1. Introduction {#sec1}
===============

Intoxications are often dangerous if not fatal conditions, but their identification is usually difficult. Delayed diagnosis may in turn result in irreversible organ failure or death. In the present case, rigorous differential diagnosis revealed massive mercury intoxication as the cause of the patient\'s clinical signs and symptoms and allowed for specific therapy.

2. Case Presentation {#sec2}
====================

A previously healthy 40-year-old man was referred to our intensive care unit from a regional hospital with aphasia, somnolence, weakness, maculopapular exanthema with palmoplantar hyperkeratosis and renal failure. He had been suffering from progressive fatigue and weakness for several weeks. On admission to the ICU the patient was somnolent, only responding with undirected movements to painful stimuli and incomprehensible sounds. Communication was not possible. Ptosis was evident, but pupils were reactive with normal accommodation to light. Severe tetraparesis (legs \> arms) was present, and the patient was hardly able to move his tongue. Muscle fasciculations were apparent, reflexes on arms and legs were nearly absent, and Babinski\'s sign was positive. The patient had an initial heart rate of 103 bpm (sinus rhythm) and a blood pressure of 150/90 mmHg in the presence of fever.

Sepsis was unlikely due to high diastolic blood pressure and nearly normal parameters of inflammation. A parainfectious syndrome was also unlikely due to normal antibody profiling and complement activities. Ultrasound revealed hepatosplenomegaly and enlarged and swollen kidneys with compacted marrow and echogenic cortex. Renal biopsy showed nonpurulent interstitial nephritis. Skin biopsy demonstrated perivascular dermatitis. Magnetic resonance imaging and lumbar puncture showed no signs of myelitis, encephalitis, and meningitis. Electroneurography and -myography demonstrated reduced nerve conduction velocity and spontaneous activity, consistent with severe axonal polyneuropathy. Thus, we suspected axonal Guillain-Barré syndrome and performed plasma exchange and immunoglobulin therapy. However the patient\'s condition further deteriorated. Tetraplegia occurred, and the patient developed progressive weakness of the respiratory muscles and coma, for which intubation and mechanical ventilation had to be started.

Due to deterioration on therapy we questioned our diagnosis. The broad clinical picture involving skin, kidneys, and the nervous system could also be caused by intoxication. While levels of many other compounds tested were normal, mercury levels were exceedingly high in peripheral blood (4255 *μ*g/l, [Figure 1](#fig1){ref-type="fig"}, [Table 1](#tab1){ref-type="table"}). Chemical analysis confirmed predominant presence of methyl mercury in blood, suggesting intoxication with organic mercury (Supplementary Materials ([available here](#supplementary-material-1){ref-type="supplementary-material"})). Despite extensive history taking and investigation, also of the social and occupational environment, the definite source of intoxication remained elusive. In retrospect, clinical signs and symptoms were consistent with severe organic mercury intoxication. Intravenous administration of the chelating agent (RS)-2,3-bis(sulfanyl) propane-1-sulfonic acid (DMPS) was combined with hemodialysis to eliminate complexed mercury. This resulted in a strong reduction of mercury levels over time ([Figure 1](#fig1){ref-type="fig"}). As methyl mercury is present in the gut of intoxicated patients and absorbed via an enterohepatic circuit \[[@B1]\], we added enteral DMPS to further enhance elimination. This bimodal chelating therapy was associated with a strong decline of blood mercury levels. In parallel mercury levels in urine and stool increased, demonstrating efficient detoxification and supporting the concept of bimodal mercury elimination. Despite the challenging diagnosis and delay in detoxification as well as the exceedingly high mercury levels, elimination was associated with improvement of clinical symptoms and organ functions. The patient gradually regained vigilance as well as motoric and neural functions. He was also successfully weaned from mechanical ventilation and hemodialysis ([Figure 1](#fig1){ref-type="fig"}). A detailed description of clinical recovery is provided in [Table 2](#tab2){ref-type="table"}. Arrhythmias did not occur during hospitalization. Eight weeks after admission to our hospital, the awake patient was sent to a rehabilitation facility. After 3 months of continuous DMPS treatment concentrations of mercury in EDTA whole blood, serum, and urine were 122, 24, and 24 *μ*g/L, respectively. Unfortunately, the patient died 7 months after discharge from our hospital from refractory status epilepticus. Autopsy revealed severe atrophy of cerebellum, pons, and medulla oblongata ([Figure 2](#fig2){ref-type="fig"}), findings that are common after severe mercury intoxication \[[@B4]\].

3. Discussion {#sec3}
=============

Mercury exposure usually occurs through ingestion of contaminated fish, contact to seed mordant, fungicides, merbromin solution (an antiseptic agent), vapour from broken thermometers \[[@B2]\], or occupational contact. Of all occurring forms, organic mercury has the highest toxicity with a total body half-life of 50 days. Prominent examples of organic mercury intoxication are Minamata disease \[[@B3]\] and the case of the American chemist Karen Wetterhahn \[[@B4]\]. In the general population the mean blood mercury level is 1.7 *μ*g/l \[[@B5]\]. While levels below 10 *μ*g/l in blood are usually nontoxic, sensitive individuals start to develop symptoms from 35 *μ*g/l on. Levels above 200-300 *μ*g/l are thought to be fatal if left untreated. In our patient initial total mercury concentration in EDTA whole blood was 4255 *μ*g/l. Shortly after start of DMPS, total mercury levels in whole blood and serum were 2929 and 899 *μ*g/L, respectively. At the same time, the concentration of methyl mercury in EDTA whole blood was 1538 *μ*g/L as determined by headspace capillary gas chromatography mass spectrometry. Thus, the majority of mercury was found intracellularly and to be methyl mercury, with a very high mercury concentration in hair samples ([Table 1](#tab1){ref-type="table"}), all of which supported and confirmed intoxication with organic mercury.

Although treatment with a chelating agent effectively lowers blood levels of mercury, its benefit on brain levels and damage is rather limited, especially in the case of methyl mercury \[[@B6]\]. With delayed onset of therapy, the chance to prevent sustained pathological effects is lower compared to immediate onset \[[@B7]\]. As such, our case demonstrates that delayed therapy of intoxication with a lethal dose of mercury is feasible and efficiently lowers blood levels. Regarding the excessive levels of mercury in our patient, we were impressed that the patient survived at all and could be sent to rehabilitation awake without organ support.

Overall, we believe that combined enteral and parenteral treatment with DMPS is beneficial in order to enhance elimination of methyl mercury by interruption of the enterohepatic circulation.
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###### 

Supplementary Methods. Description of laboratory methods used for mercury measurement.

###### 

Click here for additional data file.

![**Clinical course after mercury intoxication.**The chelating agent (RS)-2,3-bis(sulfanyl) propane-1-sulfonic acid (DMPS) was given enterally and parenterally for elimination. Black line: peripheral blood (left y axis, EDTA whole blood), red line: urine (left y axis), green line: stool (right y axis). Hg: hydrargium/mercury, MV: mechanical ventilation.](CRICC2019-4275918.001){#fig1}

![**Autopsy result.** Picture of the medulla oblongata, the cerebellum, and parts of the cerebrum as seen from caudal. The veins are very prominent, and the superficial structures especially of the cerebellum and the pons (dashed line) show marked atrophy, which is a classic late sign of mercury intoxication.](CRICC2019-4275918.002){#fig2}

###### 

**Levels of drugs or compounds tested in different compartments.** Abnormal values are highlighted with bold letters.

  **Toxicology**                                                                                
  --------------------------------------------- ------------------ ---------------------------- ----------------------
  **Compound or drug**                          **Specimen**       **Patient level**            **Normal value**
                                                                                                
  **[Initial measurements]{.ul}**                                                                
   Amphetamine & derivates                      urine              not detectable                
   Barbiturates                                 urine              not detectable                
   Benzodiazepines                              urine              not detectable                
   Buprenorphine                                urine              not detectable                
   Cocaine metabolites                          urine              not detectable                
   Morphine & Derivates                         urine              not detectable                
   Phenothiazine                                urine              not detectable                
   Tetrahydrocannabinol derivates               urine              not detectable                
   Cadmium                                      EDTA whole blood   \< 0.2 *μ*g/l                \< 1.0 *μ*g/l
   Copper                                       serum              15.6 *μ*mol/l                11.0 - 22.0 *μ*mol/l
   Lead                                         EDTA whole blood   12 *μ*g/l                    \< 120 *μ*g/l
   Zinc                                         serum              92 *μ*g/dl                   70 - 150 *μ*g/dl
   Mercury                                      EDTA whole blood   **4255** ***μ*** **g/l**     \< 2.0 *μ*g/l
   Arsine                                       urine              1.4 *μ*g/l                   \< 25.0 *μ*g/l
   Pentachlorophenol                            urine              \< 0.30 *μ*g/l               \< 5.0 *μ*g/l
   Thallium                                     EDTA whole blood   \< 0.2 *μ*g/l                \< 0.6 *μ*g/l
   Thallium                                     urine              \< 0.2 *μ*g/l                \< 0.7 *μ*g/l
                                                                                                
  [**Compartment measurements**^**∗**^ ]{.ul}                                                    
   Mercury                                      EDTA whole blood   **2929** ***μ*** **g/l**     \< 2.0 *μ*g/l
   Methyl mercury                               EDTA whole blood   **1538.0** ***μ*** **g/l**   \< 1.0 *μ*g/l
   Mercury                                      serum              **899** ***μ*** **g/l**      \< 2.0 *μ*g/l
   Mercury                                      urine              **360** ***μ*** **g/l**      \< 1.0 *μ*g/l
   Mercury                                      hair               **713** ***μ*** **g/g**      \< 2.0 *μ*g/g

^*∗*^: after start of treatment with DMPS.

###### 

 **Clinical course during detoxification with DMPS.**

  **Clinical Course**   
  --------------------- ----------------------------------------------------------------------
  **Day** ^**∗**^       **Observation**
                        
  3                     pupils beginning to react to light
  4                     short periods of assisted ventilation
  7                     muscle fasciculations absent
  9                     spontaneous eye opening
  10                    spontaneous breathing
  11                    exanthema starts to decline
  14                    continuous spontaneous breathing
  15                    eye opening to verbal command
  16                    change from CRRT to intermittent dialysis
  17                    increasing vigilance
  19                    patient startles upon verbal command reflexes start to return
  20                    first spontaneous movement of extremities
  23                    first successful mobilization (with assistance) exanthema diminishes
  25                    increasing extremity movement
  30                    switch from dialysis to ultrafiltration only
  31                    visual fixation
  33                    patient mobilized from bed to chair
  34                    all standard reflexes bilaterally reestablished
  37                    spontaneous directed movement of all extremities
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